BeOne Medicines showcased updated Phase 3 data for BRUKINSA at EHA 2025, a high-profile hematology conference that often moves biotech names on data readouts. The company reported FY2025 revenue of $5.3B, up 40.2% year-over-year, with an 87.5% gross margin — a hallmark of a blockbuster oncology drug gaining market share across CLL, MCL, and WM indications. Net margins remain thin at 5.4%, suggesting heavy ongoing R&D and commercial spend that leaves earnings sensitive to competitive or clinical shocks.

The EHA presentation itself is the near-term catalyst: positive updated survival or response data could reinforce BRUKINSA's positioning against AstraZeneca/AbbVie's acalabrutinib and ibrutinib franchises, while any sign of plateauing efficacy or safety signals would pressure the already-slim bottom line. Investors should watch for head-to-head comparator data, any new indication expansions, and management commentary on pricing dynamics in a crowded BTK inhibitor market.